GSK · story · 14 November
GSK · 11 headlines from 9 outlets, on 14 November 2026.
GSK received a positive CHMP opinion for a Bexsero booster dose for adolescents.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
TradingView is the largest at 10.0, ahead of AskTraders (10.0). MarketScreener is the smallest at 9.2.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| TradingView | 10.0 |
| MarketScreener | 9.2 |
| AskTraders | 10.0 |
| Sharecast | 10.0 |
| DirectorsTalk Interviews | 10.0 |
| TipRanks | 10.0 |
| London South East | 9.7 |
| Proactive Investors UK | 9.2 |
| Stock Titan | 9.2 |
| Outlet | Headlines | Average tone |
|---|---|---|
| TradingView | 2 | +10.0 |
| MarketScreener | 2 | +9.2 |
| AskTraders | 1 | +10.0 |
| Sharecast | 1 | +10.0 |
| DirectorsTalk Interviews | 1 | +10.0 |
| TipRanks | 1 | +10.0 |
| London South East | 1 | +9.7 |
| Proactive Investors UK | 1 | +9.2 |
| Stock Titan | 1 | +9.2 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Favourable EU opinion for its meningitis vaccine booster. |
| +10.0 | Favourable EU opinion for its meningitis B vaccine booster. |
| +10.0 | Favourable European regulatory opinion for its meningitis vaccine booster. |
| +10.0 | European regulator panel backs booster dose for its meningitis vaccine. |
| +10.0 | Regulatory announcement of favourable opinion for vaccine booster. |
| +10.0 | Company announces favourable regulatory opinion for its vaccine booster. |
| +10.0 | Positive regulatory opinion for single-dose meningitis vaccine booster. |
| +9.7 | EU panel backs adolescent booster for its meningitis B vaccine. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +9.2 | Meningitis B booster advances toward European approval. |
| +9.2 | Long-term data supports the case for the booster's labelling. |
| +8.3 | EU panel supports its meningococcal vaccine for use in newborns. |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.